News

This is a Mint Premium article gifted to you. Subscribe to enjoy similar stories.

The pharmaceutical sector is witnessing a strong investor focus, supported by rising global demand, resilient exports, and strong domestic healthcare spending.

India’s pharma exports crossed $30 billion (bn) in FY25, aided by United States Food and Drug Administration (US FDA) approvals and expanding generics reach.

However, pricing pressures in the US, regulatory scrutiny, and raw-material cost volatility continue to pose global headwinds.

We break down the two pharma players, comparing their business mix, profitability, and growth strategies to determine which one is stronger in India’s evolving healthcare landscape.

Zydus Lifesciences Ltd is an integrated, global life sciences company operating across the entire value chain in research, manufacturing, and marketing of pharmaceutical and wellness products.

Its core purpose is empowering people with the freedom to live healthier lives through science and pathbreaking discoveries.

In Q1 FY26, the company demonstrated execution excellence in US formulations and saw its branded India formulations business outpace market growth, supported by robust profitability.

Rubicon Research is an innovation-driven pharmaceutical formulations company specialising in speciality products and drug-device combinations. It maintains a complete focus on regulated markets, particularly the US.

Leveraging intensive R&D, the company had 72 active ANDAs (applications to sell generic drugs in the US) and 9 active NDAs (applications to sell new, original drugs in the US) approved by the USFDA as of June 2025.

Notably, it was the fastest-growing Indian pharmaceutical formulations company among its assessed peers between FY23 and FY25.

Zydus Lifesciences

172,374

195,474

232,415

65,737

Rubicon Research

3,935.19

8,538.89

12,842.72

3,524.94

Source: Company FY25 Report and RHP Filings

Zydus Lifesciences reported a 19% YoY revenue growth in FY25, led by strong performance across all segments.

The US business crossed the $1 bn mark, driven by new launches and volume growth, while India formulations and Consumer Wellness delivered robust double-digit growth.

In Q1FY26, revenue rose 6% YoY, led by international markets (up 37%). Management targets double-digit FY26 growth, driven by India and global markets, with future focus on biologics, vaccines, MedTech, and CDMO expansion.

At the same time, Rubicon Research recorded strong growth over the years, led by new product launches, volume expansion, and higher pricing in the US market.

In FY24, revenue surged 117% YoY, followed by a 50.4% rise in FY25, supported by the addition of new generic and speciality products and the Validus Pharma acquisition. In Q1FY26, revenue grew 11.3% YoY, driven by improved product mix and higher margins.

The management plans to sustain momentum through R&D-led portfolio expansion, speciality product growth, and capacity upgrades for long-term scalability.

Zydus Lifesciences

38,599

53,843

70,585

20,885

Rubicon Research

439.72

1,730.90

2,678.93

797.44

Zydus Lifesciences

25,691

38,507

47,451

14,668

Rubicon Research

-168.88

910.12

1,343.61

433.01

Zydus Lifesciences

22.4%

27.5%

30.4%

31.8%

Rubicon Research

10.49%

19.84%

20.67%

22.34%

Zydus Lifesciences

14.9%

19.7%

20.4%

22.3%

Rubicon Research

4.03%

10.43%

10.37%

12.13%

Source: Company FY25 Report and RHP Filings

Zydus Lifesciences' profitability improved sharply from FY23 to FY25, achieving record Ebitda margins of 30.4% in FY25.

Margin gains were driven by a better product mix, cost efficiencies, and strong growth in India formulations and Consumer Wellness. Net profit rose 23% YoY in FY25, supported by high-margin products like Mirabegron and the Saroglitazar franchise.

In Q1 FY26, margins remained strong at 31.8%. For FY26, management expects margins around 26%, amid pricing pressure, higher R&D spend, and Revlimid competition.

However, Rubicon Research turned profitable in FY24 after posting a net loss of ₹168.88 m in FY23, driven by 117% revenue growth and a shift toward higher-margin speciality products.

Net profit rose 638.9% in FY24 and 47.6% in FY25, supported by improved cost control, product mix, and the Validus Pharma acquisition.

By Q1FY26, profit jumped 69% YoY with EBITDA margin up to 22.3%, reflecting strong speciality portfolio growth, better pricing power, and operational efficiency gains.

Investing in pharma stocks can be exciting, especially when a single drug approval can move the stock overnight. But it’s also a high-risk, high-reward space, and there are risks every investor should know:

India’s pharmaceutical sector stands at a turning point driven by rising healthcare demand, global generic dominance, and growing R&D capabilities.

With strong export potential and increasing focus on innovation, top Indian pharma companies are well-positioned for long-term growth.

However, investors must closely track regulatory actions, patent cycles, and pricing pressures, as these factors can significantly influence earnings stability. A balanced approach combining growth potential with careful risk assessment remains key to navigating India’s evolving pharma landscape.

It's important to conduct thorough research on financials and corporate governance before making investment decisions, ensuring they align with your financial goals and risk tolerance.

Happy Investing.

Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such.

This article is syndicated from Equitymaster.com

Download the Mint app and read premium stories

Log in to our website to save your bookmarks. It'll just take a moment.

You are just one step away from creating your watchlist!

Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.

Your session has expired, please login again.

You are now subscribed to our newsletters. In case you can’t find any email from our side, please check the spam folder.

This is a subscriber only feature Subscribe Now to get daily updates on WhatsApp